



DMSG Scientific Symposium

“BCMA targeted therapy – uses and perspectives”

Thursday, 3 November 2022

First Hotel Grand, Jernbanegade 18, 5000 Odense C, Denmark

Program (updated on 2 October 2022)

- 13.00-14.00** **Arrival and lunch**
- 14.00-14.10** **Welcome.** Emil Hermansen, chair DMSG
- 14.10-14.50** ***How do we treat MM patients in Germany.*** Professor Hartmut Goldschmidt, Heidelberg, Germany.
- 14.50-15.30** ***Improving the targets in multiple myeloma: Future CAR-T strategies.*** Jakub Krejcik, MD, PhD. Odense University Hospital.
- 15.30-16.00** **Coffee and posters**
- 16.00-16.30** ***Upcoming BCMA studies.*** Fredrik Schjesvold, MD, PhD. Oslo Myeloma Center, Norway.
- 16.30-17.00** ***Side effects of BCMA targeted therapies.*** Sarah Farmer, MD, PhD. Vejle Hospital.
- 17.00-17.20** **Panel discussion: *Optimal patient selection and sequencing of BCMA therapies?***
- 17.20-17.30** **Break**
- 17.30-18.00** ***DMSG Young Investigator Award 2022.***
- Introduction and award: Emil Hermansen & company representative
- Acceptance speech by awardee
- 18.00** ***Adjourn***

Registration at myeloma.dk: <https://myeloma.hematology.dk/index.php/dmsg>

The symposium is sponsored by pharmaceutical companies and the International Myeloma Foundation

